title: Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
authors.forename: Michelle
authors.initials: M
authors.lastname: Fanale
authors.forename: Luis
authors.initials: L
authors.lastname: Fayad
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Felipe
authors.initials: F
authors.lastname: Samaniego
authors.forename: Mary Joy
authors.initials: MJ
authors.lastname: Liboon
authors.forename: Cesar
authors.initials: C
authors.lastname: Nunez
authors.forename: Sandra
authors.initials: S
authors.lastname: Horowitz
authors.forename: Paolo
authors.initials: P
authors.lastname: Anderlini
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
authors.forename: Yuan
authors.initials: Y
authors.lastname: Ji
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D016190:Carboplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D012008:Recurrence; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide